Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management
PITTSBURGH, June 26, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled 'The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds', this review is the first to systematically compile data from 17 studies on fluorescence imaging.1 It conclusively establishes the crucial role of MolecuLight's technology in enhancing wound assessment by equipping clinicians with real-time, actionable information to effectively detect elevated bacterial burden, fundamentally transforming wound management.
'This new publication is a crucial step forward for MolecuLight. It provides a comprehensive review of existing evidence, further underscoring the essential role of MolecuLight's fluorescence imaging in elevating wound care,' said Anil Amlani, CEO of MolecuLight. 'Bacterial bioburden leads to infections and is a critical factor inhibiting wound healing, and this paper clearly articulates how our technology empowers clinicians to not only identify the presence and location of bacteria but also to guide targeted interventions. Ultimately, this leads to faster and more effective healing for patients, further strengthening the growing body of evidence supporting our technology's profound impact.'
'As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds,' said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. 'The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care.'
This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,2 frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to:
MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs.
About MolecuLight Corp.
MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
View original content to download multimedia: https://www.prnewswire.com/news-releases/landmark-study-affirms-moleculights-efficacy-in-real-time-bacterial-detection-for-improved-wound-management-302491652.html
SOURCE MolecuLight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
11 hours ago
- Associated Press
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program
Canada's Largest Medical Cannabis Company Offers the Country's Most Inclusive Medical Cannabis Pricing Program NASDAQ | TSX: ACB EDMONTON, AB, June 26, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 CAD for Aurora patients through 'As over half of the country's adult population fits within this income threshold, our compassionate pricing program represents the most accessible, inclusive pricing plan to access medical cannabis in Canada,' says Geoff Hoover, SVP of Canadian Commercial at Aurora. 'We're committed to breaking down barriers to access high quality medical cannabis, and this change empowers more patients to explore different treatment options at pricing they can afford.' The changes to the compassionate pricing program are available alongside new medical cannabis products, including: In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit for more information and to connect with the Aurora client care team for further support. About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol 'ACB'. Forward Looking Information This news release includes statements containing certain 'forward-looking information' within the meaning of applicable securities law ('forward-looking statements'). Forward-looking statements are frequently characterized by words such as 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company's expanded compassionate pricing program, and associated benefits for patients. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading 'Risk Factors' in the Company's annual information form dated June 17, 2025 (the 'AIF') and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. View original content to download multimedia: SOURCE Aurora Cannabis Inc.
Associated Press
12 hours ago
- Associated Press
Landmark Study Affirms MolecuLight's Efficacy in Real-Time Bacterial Detection for Improved Wound Management
PITTSBURGH, June 26, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, proudly announces the publication of a landmark systematic review by researchers at Trinity College Dublin and the Royal College of Surgeons in Ireland (RCSI). Titled 'The Clinical Utility of Autofluorescence Imaging for Bacterial Detection in Wounds', this review is the first to systematically compile data from 17 studies on fluorescence imaging.1 It conclusively establishes the crucial role of MolecuLight's technology in enhancing wound assessment by equipping clinicians with real-time, actionable information to effectively detect elevated bacterial burden, fundamentally transforming wound management. 'This new publication is a crucial step forward for MolecuLight. It provides a comprehensive review of existing evidence, further underscoring the essential role of MolecuLight's fluorescence imaging in elevating wound care,' said Anil Amlani, CEO of MolecuLight. 'Bacterial bioburden leads to infections and is a critical factor inhibiting wound healing, and this paper clearly articulates how our technology empowers clinicians to not only identify the presence and location of bacteria but also to guide targeted interventions. Ultimately, this leads to faster and more effective healing for patients, further strengthening the growing body of evidence supporting our technology's profound impact.' 'As a co-author of this systematic review and an academic and researcher who utilized MolecuLight's technology in practice, I can attest to the profound impact it has on clinicians' ability to manage complex wounds,' said study author Rosemarie Derwin, PhD, MSc, PG Dip, BNS, RGN, RNT, experienced nurse, educator, and researcher at the School of Nursing and Midwifery, Trinity College Dublin. 'The real-time visualization of bacteria provides immediate practical information that guides treatment decisions, leading to more effective care plans and ultimately, better outcomes for patients. This study affirms what many of us have seen clinically: MolecuLight is a vital asset in modern wound care.' This detailed systematic review of current evidence underscores the capability of MolecuLight devices to identify clinically significant levels of bioburden. This bioburden, frequently undetectable via visual inspection and present in over 80% of chronic wounds,2 frequently causes infection and necessitates targeted intervention. By visualizing bacterial fluorescence, clinicians are equipped to: MolecuLight continues to build on a robust foundation of clinical evidence. With over 100 peer-reviewed publications demonstrating the utility and impact of its fluorescence imaging technology, this systematic review powerfully reinforces that managing bacterial burden is essential for effective wound care. It affirms that MolecuLight devices provide an invaluable and proven tool for clinicians to achieve this, by enabling more precise and targeted interventions that hold strong promise for improved healing trajectories and enhanced patient quality of life. The company remains dedicated to advancing wound care through innovative solutions that improve patient lives and reduce healthcare costs. About MolecuLight Corp. MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only Class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. View original content to download multimedia: SOURCE MolecuLight
Yahoo
a day ago
- Yahoo
Craft Telemedicine Launches to Redefine Specialty Care with Human-Centered
Revolutionary no-subscription telemedicine model gives patients complete control over specialized compounded medications and pharmacy choice TULSA, Okla., June 25, 2025 /PRNewswire/ -- Craft Telemedicine today announced the official launch of its innovative telemedicine platform that eliminates subscription models and empowers patients with unprecedented choice and transparency in their healthcare decisions. Unlike traditional telehealth platforms that lock patients into monthly subscriptions and limited pharmacy networks, Craft Telemedicine operates on a pay-per-prescription model. Patients pay one transparent fee to receive their prescription and maintain complete freedom to fill it at any pharmacy of their choice. "Clarity is a form of care," said Arlee Riveland, CEO and Co-Founder. "I didn't set out to found a healthcare company, but I did set out to build human-centered tools that solve real problems. And this one matters." Addressing Critical Access Gaps Craft Telemedicine launches with high-quality compounded medications, beginning with Low-Dose Naltrexone and Methylene Blue—specialized treatments often difficult to access through traditional healthcare channels. "When patients search for Methylene Blue online, they're flooded with options that range from aquarium treatments to industrial dyes," said Jack Korbutov, Co-Founder and pharmacist at The Art of Medicine. "Many people don't realize that what they're buying isn't pharmaceutical-grade and heavy metal-free. This could actually be harmful." The platform was built in partnership with The Art of Medicine to ensure patients receive pharmaceutical-grade compounded medications with rigorous quality standards. The founding team includes Stephen Stearman, who brings extensive healthcare entrepreneurship experience through his leadership of multiple healthcare companies under the Craft Health Group. Expanding Nationwide Network Craft Telemedicine is actively seeking partnerships with high-quality compounding pharmacies nationwide, positioning itself as the preferred telemedicine platform for pharmacies seeking to grow their patient base without compromising their values or independence. "We're building a network of trusted compounding pharmacies that share our commitment to quality and patient care," explained Riveland. "We're not just delivering prescriptions—we're restoring agency to patients." The platform is currently available in 25 states with plans to serve all 50 states by 2026. Patients can access the platform at with transparent, pay-per-prescription pricing and no subscription fees. Company Contact: Arlee Riveland, CEO & Co-FounderEmail: arlee@ View original content to download multimedia: SOURCE Craft Telemedicine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
